

A NEW FRONTIER FOR IMMUNO-ONCOLOGY

Immunicom is expanding the use of immuno-oncology therapies through our **Immunopheresis® subtractive therapy platform**, which activates the immune system to attack solid tumors and reduce inflammation **without** the toxicity, side effects, and complications of conventional therapies.

Immunopheresis® Platform Therapy



High-affinity molecular capture platform



Novel targeted IO delivery cartridge



'Designer' ligand development

Three Global Clinical Trials with Over 2,000 Treatments Administered

Immunopheresis is being tested on **multiple cancers** where the patient population consists of patients with end-stage, refractory, **metastatic cancers** who no longer respond to other therapies.

Benefits

- + Adjunct treatments for end-stage, metastatic, refractory cancers
- + A non-toxic solution to safely neutralize any cytotoxic or suppressive factors that impede therapy response



Immunicom

CLINICAL AND REGULATORY PROGRESS

1

CE MARK EUROPEAN APPROVAL FOR mTNBC

2

FDA BREAKTHROUGH DEVICE DESIGNATION

3

NIH / NCI SPONSORED BREAST CANCER TRIAL

4

ISO 13485 CERTIFIED MANUFACTURING



NEW HOPE FOR END-STAGE CANCER PATIENTS

What does the oncology clinical data show on Immunicom's initial product, LW-02?*

Viable and safe "Treatment of Last Resort" with high quality of life

Meets or exceeds top oncology drugs when used in combination or as a monotherapy

75% reduction in brain metastases

Extends Overall Survival and Progression Free Survival in heavily pre-treated, refractory patients

Scalability

Immunopheresis therapy is administered in oncology infusion centers like other IO infusion drugs, leveraging existing processes and clinical resources.

Out-Licensing

Immunopheresis therapy is an ideal candidate for adjunct therapy and creates numerous product development opportunities for existing IO therapies to potentially enhance patient response and extend market protections.

Series C Funding and Growth

Immunicom has raised \$50M in equity financing and strategic partnerships to-date. The Company is in the process of securing Series C investment round and planning for a potential IPO in the next 20 months.

Immunopheresis Platform: Rapid Development of Therapeutic Molecules



Product

LW-02

EN-06

RJ-12

DM-01

MB-03

Target for Capture

sTNF Receptor for TNF- α upregulation

Interleukin 6 (IL-6) cytokine

Soluble PD-L1 Immune Checkpoint Protein

VEGF Angiogenic Growth Factor

Soluble CTLA-4

Scan the code to watch Immunicom's video:

*Immunicom's Immunopheresis® therapy, including the LW-02 Column, has not been approved by the US Food and Drug Administration and is an investigational therapy in all of Immunicom's ongoing clinical research studies.

CONTACT US: Johan Louw
+1 (281) 660 1815
johan.louw@immunicom.com

Ibrahim Basit
+1 (432) 770 8065
ibrahim.basit@immunicom.com

